Ocular Therapeutix Extends Wet AMD Trial, Eyes Long-Term Data

Event summary

  • Ocular Therapeutix initiated a 36-month extension trial (SOL-X) for AXPAXLI (OTX-TKI) in April 2026.
  • The trial enrolls patients who completed the two-year SOL-1 trial, aiming to assess long-term safety and efficacy.
  • SOL-X will administer AXPAXLI every 24 weeks, with additional anti-VEGF injections at investigator discretion.
  • The trial seeks to evaluate the impact of delayed AXPAXLI initiation compared to those initially on aflibercept.

The big picture

Ocular Therapeutix is attempting to address a significant unmet need in wet AMD treatment: sustained efficacy with reduced injection frequency. The SOL-X trial represents a bet that continuous VEGF suppression can fundamentally alter disease progression, potentially displacing existing therapies and expanding the addressable market. Success hinges on demonstrating a clear clinical benefit over the long term, which is crucial for securing broader adoption and justifying the premium pricing often associated with novel therapies.

What we're watching

Clinical Outcomes
The data from SOL-X will be critical in determining if AXPAXLI's durability translates to meaningful, long-term improvements in patient vision and a reduction in fibrosis and atrophy, which will influence its commercial viability.
Regulatory Pathway
The FDA's assessment of the SOL-X data, particularly regarding the impact of delayed initiation, will shape the label and potentially influence the commercial adoption of AXPAXLI.
Market Adoption
The extent to which SOL-X data supports a reduction in treatment burden will directly affect patient retention and the overall market opportunity for AXPAXLI, potentially impacting Ocular Therapeutix's revenue projections.